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Purpose: To investigate the clinical outcomes of combined orbital radiotherapy and systemic glucocor-
ticoids for patients with refractory Graves’ ophthalmopathy (GO).
Materials and methods: The records were retrospectively reviewed of six patients with active moderate-
to-severe GO who had been refractory to steroid therapy alone and treated with combined orbital
radiotherapy and systemic glucocorticoids. All patients had already received one or more trial of steroid
therapy prior to radiotherapy. Two patients had recurrence after steroid cessation, and four were unable
to taper corticosteroids partially or completely. Two patients experienced relapse compressive optic
neuropathy during tapering of glucocorticoids. The radiation dose was 20 Gy at 2 Gy/fraction. Presenting
signs especially for disease activity and severity, treatment outcomes, and side effects were assessed.
Results: After combined therapy, complete cessation of corticosteroid therapy and stabilization of disease
without recurrence was achieved in all patients. The clinical activity score decreased from 6.0 to 2.5
(p ¼ 0.04). The ophthalmopathy index decreased from 8.2 to 5.7 (p ¼ 0.05), with signiﬁcant improvement
in soft tissue sign (p ¼ 0.03) and extraocular muscle movement (p ¼ 0.03). Both patients with relapse
dysthyroid optic neuropathy regained their vision. Side effects of radiotherapy included posterior
subcapsular cataract formation in one patient.
Conclusion: Combined orbital radiotherapy and systemic corticosteroids can help to achieve stable dis-
ease and cessation of corticosteroid without recurrence in patients with refractory GO. This technique
achieves greater improvement in clinical activity, soft tissue inﬂammation, and ocular motility.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Graves’ ophthalmopathy (GO), the most common and important
extrathyroidal manifestation of Graves’ disease, is thought to be an
inﬂammatory disorder of autoimmune background.1 Althoughmost
GO patients have a mild and nonprogressive clinical course, it may
lead to functional disability (diplopia, exposure keratitis, and vision
impairment) and social disturbance (disﬁguring features), which
profoundly inﬂuence the quality of life of affected individuals.2 Theproduct mentioned in the
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e Ophthalmologic Society of Taiwclear and indisputable mechanism of the pathogenesis of GO re-
mains to be elucidated, and it may represent a result of a complex
interplay between endogenous and environmental factors.3,4 Sys-
temic corticosteroid and orbital radiotherapy (OR) remains the
mainstay treatment for GO. Systemic glucocorticoids (GCs) are often
effective, butﬂare-upof ocular symptoms is commonwhen thedose
of GCs is tapered or withdrawn. In some randomized clinical trials,
OR was reported to be as effective as oral GCs 5 and the combined
treatmentwithOR andoralGCswasmore effective than eitherORor
oral GCs alone.6e8 However, the efﬁcacy of combination of OR and
GCs for patients with GO refractory to GCs therapy remains to be
determined. Here we investigate the clinical outcome of combined
treatment with OR and intravenous GCs in patients with relapse GO
when GCs are tapered or withdrawn.an. Published by Elsevier Taiwan LLC. All rights reserved.
Table 2
Change in clinical parameters of six patients after treatment with combined orbital
radiotherapy and systemic glucocorticoids.
Pretreatment Post-treatment p
Clinical activity score 6.00  0.63 2.50  1.67 0.04
Ophthalmopathy index 8.17  1.47 5.67  1.21 0.05
Soft tissue sign 2 .00  0 1.17  0.41 0.03
Proptosis 1.00  0.58 0.83  0.41 0.28
Extraocular muscle movement 2.00  0 1.17  0.41 0.03
Cornea involvement 1.33  0.52 1.17  0.41 0.32
Sight loss 0.64  0.36 0.82  0.29 0.47
Data are presented as mean  SD.
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2.1. Patients
The medical records were retrospectively reviewed of all active
moderate-to-severe GO patients who were treated for refractory
GO with combination of OR and GCs at a tertiary medical center
between 2009 and 2012. All patients who had persistent or recur-
rent GO, even after one or more trials of GCs therapy, were enrolled
for this study. Exclusion criteriawere any ocular diseases other than
GO; regular drug ingestion, or antioxidant use; pregnancy; and
age < 35 or > 80 years. Individuals who had been receiving
radiotherapy or surgical decompression for GO were also excluded.
This study was performed in accordance with the Declaration of
Helsinki, and informed consent was obtained from the patients.
2.2. Treatment with combination of OR and GCs
All patients initially received intravenous methylprednisolone
250 mg every 6 hours for 3 consecutive days, follow by oral pred-
nisolone (0.7 mg/kg/day) for 4 weeks. Oral prednisolone was then
tapered slowly to discontinuation in 3e4 months in all patients. OR
was started after intravenous methylprednisolone therapy and all
patients were treated bilaterally. A total of 20 Gy was delivered to
each eye in 10 fractionated doses over a period of 2 weeks.
2.3. Ophthalmologic examinations
All participants received ophthalmologic evaluation by the same
ophthalmologist (C.C. Tsai) prior to and after combination treat-
ment. The patients were followed-up every 2 weeks for the ﬁrst 2
months, and then every 1e2 months. Baseline characteristics of
the patients, their presenting symptoms, biochemical data,
outcome, and side effects after combined OR and systemic GCs
were collected. Ophthalmological investigations including best-
corrected visual acuity, intraocular pressure, funduscopic exami-
nation, and especially the disease activity and severity of GO were
assessed prior to and after combined treatment. The clinical activity
of GO was scored according to Mourits et al,9 and the subsequent
revision of an ad hoc international committee using the seven-point
clinical activity score (CAS).10 It is based on seven signs of inﬂam-
mation of the orbit (spontaneous retrobulbar pain, pain on
attempted eye movements, conjunctival hyperemia, eyelid redness,
chemosis, swelling of the caruncle, and swelling of the eyelids). One
point is given for any manifestation, and the score may range from
0 (no activity) to 7 (high activity). The patients with a CAS 3 were
considered as having active GO. The severity of the ophthalmop-
athy was scored according to the ophthalmopathy index (OI), based
on the NOSPECS (No signs or symptoms; Only signs; Soft tissue;
Proptosis; Extraocular muscle; Cornea; Sight loss) classiﬁcation
ranging from 0 points to 15 points (0e3 points were given for 5
clinical parameters of the disease based on the severity of soft
tissue involvement, proptosis, extraocular muscle involvement,
corneal involvement, and sight loss, respectively).8 The deﬁnition ofTable 1
Modiﬁed grading for ophthalmic index: the SPECS score.
Grade S P
1 Slight redness, chemosis, periorbital edema,
minimal symptoms
>18e21 mm
2 Moderately severe redness, chemosis,
periorbital edema, moderate symptoms
>21e25 mm
3 Severe redness, marked edema, severe symptoms >25 mm
S ¼ soft tissue involvement; P ¼ proptosis; E ¼ extraocular muscle involvement; C ¼ coproptosis mentioned above was adjusted according to racial vari-
ation, and the mean value of exophthalmos in normal Taiwanese
adults is 13.91  2.33 mm.11 Modiﬁed grading for ophthalmopathy
index score is shown in Table 1. According to the consensus
statement of the European Group on Graves’ Orbitopathy on
management of GO, patients having any one or more of the
following were considered as moderate-to-severe GO: lid
retractions  2 mm, moderate or severe soft tissue involvement,
exophthalmos  3 mm above normal for race and gender; and
inconstant or constant diplopia.12
2.4. Statistical analysis
Statistical analysis was performed using GNU PSPP software
version 0.7.9-gf00c84 (http://pspp.awardspace.com/). The data
obtained are expressed as mean values  standard deviation.
Comparisons of CAS and OI difference between pretreatment and
post-treatment were performed with the Wilcoxon Signed Rank
test. A p value < 0.05 was considered statistically signiﬁcant.
3. Results
Seven patients met the inclusion criteria; however, one patient
was lost to follow-up soon after treatment. Therefore six patients
(1 man and 5 women) with a mean age of 56.7 years (range, 51e67
years) were analyzed. Two patients had recurrence GO after GCs
cessation, and four was unable to taper GCs partially or completely.
Two patients who refused decompression surgery and experienced
relapse dysthyroid optic neuropathy (DON) during tapering of GCs
were included. The mean follow-up time was 24.1 months (range
12e34 months).
Table 2 shows the change of clinical parameters of six patients
after treatment with combined OR and systemic GCs. Themean CAS
of patients decreased signiﬁcantly from 6.0 prior to combined
therapy to 2.5 (p ¼ 0.04). The mean OI of patients decreased from
8.2 prior to therapy to 5.7 (p ¼ 0.05). Subgroup analysis on ﬁve
parameters of OI showed signiﬁcant improvement on soft tissue
sign (p ¼ 0.03) and extraocular muscle movement (p ¼ 0.03),
whereas no signiﬁcant differences occurred in proptosis, corneal
involvement, or sight loss. However both patients with DON
regained and improved their best corrected visual acuities (worstE C S
Infrequent diplopia, not in
primary gaze
Slight stippling 6/7.5e6/12
Frequent diplopia, moderate
limitation of movement
Marked stippling 6/15e6/30
Severe constant muscle
dysfunction
Ulceration <6/30
rneal involvement; S ¼ sight loss.
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GC cessation. None required surgical intervention to preserve their
vision or restore binocular vision. During the follow-up period,
none of the patients experienced any severe late complications
such as radiation-induced retinopathy, corneal ulceration, or
perforation. However, one patient developed posterior subcapsular
cataract at 22 months after adjunctive OR and underwent cataract
surgery.
4. Discussion
Intravenous GC is the recommended ﬁrst-line treatment for
moderate to severe and active GO by the European Group on
Graves’ Orbitopathy.12 However, medical treatments for patients
with recurrent or persistent GO after systemic GCs still represent a
major clinical and therapeutic challenge. Many patients may
eventually require rehabilitative surgery for functional or cosmetic
morbidity. Our study showed that a combination of OR and intra-
venous GCs is effective particularly on clinical activity, ocular
motility, and soft tissue inﬂammation for patients with GO re-
fractory to steroid therapy.
OR has been used to treat GO for several decades and is often
thought to be a safe second-line treatment. The rationale for using
low-dose radiotherapy on GO is related to the anti-inﬂammatory
effect, in particular the modulation of cytokines and adhesion
molecules expression on activated leukocytes.13 In addition, OR
may reduce the synthesis and secretion of glycosaminoglycans by
orbital ﬁbroblasts.14 Two randomized clinical trials (RCTs)
conﬁrmed that OR is effective on ocular motility in patients with
either mild GO or moderate-to-severe GO,5,15 and two other RCTs
addressed the combination effect of oral GCs and OR is more
effective than either treatment alone.7,8 However, one RCT from the
Mayo Clinic failed to ﬁnd a clinically signiﬁcant beneﬁt of OR on GO,
as compared to sham irradiation.16 Three recent systematic litera-
ture reviews on OR alone in GO have reached different conclusions
about its efﬁcacy; one was positive17 and two negative.18,19 These
controversial ﬁndings may be due to selection bias, especially
whether patients had longer or shorter duration of disease, variable
severity and activity of GO, and different prior treatment. Other
factors implicated in the variable response to OR include issues
regarding different outcome measures, varied stage of the disease,
and the use of adjunct corticosteroid therapy. There is agreement
that OR alone is less effective on exophthalmos, long-standing or
inactive GO, and those failing to respond to GCs.20
Although some underscore the role of OR alone on GO, most
studies address that OR combined with GCs is more effective than
monotherapy in reducing global indices of GO,7,8,19 suggesting a
synergistic effect of the combined treatment. Both OR and GCs are
reported to reduce inﬂammatory processes, with GCs acting within
days, whereas the response fromORmay takeweeks or months, but
lasts longer. A preliminary study further reported that combination
of orbital irradiation and systemic steroids (intravenous followed by
oral steroid) is more effective than steroids alone in the treatment of
active moderate-to-severe GO.21 In addition, the combined therapy
using the intravenous glucocorticoids was more effective than the
combined treatment using the oral glucocorticoids (responders,
87.8% vs. 63.4%; p< 0.02) and better tolerated.6 Therefore,we choose
combined OR and intravenous GCs for patients who had active
moderate-to-severe GO and failed to respond to one or more prior
systemic steroid. Our current ﬁndings reveal that the efﬁcacy of
combined treatment is more pronounced on clinical activity score,
soft tissue changes, and ocularmotility, andmuch less impressive on
proptosis, exposure keratopathy, and vision change. Two cases with
DON did regain their vision after combined treatment, even though
there was no signiﬁcant vision change among all patients aftertreatment. Thismay be partially due tomost patients (4 of 6 cases) in
our study having no vision impairment prior to treatment.
Complete cessation of corticosteroid therapy and stabilization of
GO without recurrence was obtained after combined treatment in
all patients, including two cases with relapse DON. The ability to
discontinue GCs shortly after adjunct OR has been reported.22,23
Sight-threatening GO usually occurs in the context of DON. DON
can be treated by systemic GCs, surgery, or both. Relapse of DON
may occur when systemic GCs are withdrawn and often require
decompression surgery.12 Our current ﬁndings showed that OR in
combination with systemic GCs may have some beneﬁt for relapse
DON. Guy et al and Bartalena et al have documented beneﬁt using
radiotherapy in conjunctionwith systemic steroids for treatment of
DON.24,25 Another study by Kazim et al found that radiotherapywas
more effective than high-dose GCs in relieving compressive optic
neuropathy.26 Dolman et al suggest combined radiotherapy (20 Gy
over 2 weeks) with systemic GCs may be effective and delay or
avoid surgery in cases of DONwith incomplete or short-lived visual
improvement after intravenous GCs.27 They also noted that post-
operative (orbital decompression) OR had the extra beneﬁt to
prevent and control relapses in DON in cases with progressive
muscle expansion.27
Potential complications of OR include cataract development,
retinopathy, and tumor formation. The most common late effect
observed was cataract development, which occurred more
frequently in older patients. In the current study, cataract developed
in one 67-year-old patient (16.7%), and was reversible with cataract
surgery. Radiation retinopathy after OR for GO was relatively rare
and had been reported in cases that were accidentally treated with
an excessive radiotherapy dose.28 Retinal microvascular changes
may develop in diabetic patients treatedwith radiotherapy. The risk
of radiation-induced cancer is extremely low, Snijders-Keilholz et al
calculated a cumulative probable risk of tumor induction after retro-
orbital irradiation for GO over a lifetime of up to 1.2%.29 For that
reason, radiotherapy in GO is commonly restricted to patients older
than 35 years and lifelong surveillance is advised.
Most previous study aimed to discuss the efﬁcacy of combined
treatment as an initial treatment for GO patients or they often
included both groups of patients as initial treatment and thosewith
poor response or intolerance to systemic steroids,6e8,15,21 whereas
we have investigated the clinical outcomes of combined treatment
for refractory cases only. However, because of limited cases in this
study, more studies are warranted to provide additional informa-
tion about the precise effect of adjunctive OR on the refractory GO.
In conclusion, adjunctive OR with systemic GCs provides an
alternative treatment choice for patients with active moderate-to-
severe GO refractory to steroid therapy alone.References
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